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Summary
Factor IX deficiency (hemophilia B) is less common than factor VIII deficiency (hemophilia A) 
and innovations in therapy for hemophilia B have generally lagged behind those for hemophilia A. 
Recently the first sustained correction of the hemophilia bleeding phenotype by clotting factor 
gene therapy has been described using recombinant adeno-associated virus (AAV) to deliver 
factor IX. Despite this success, many individuals with hemophilia B, including children, men with 
active hepatitis, and individuals who have pre-existing natural immunity to AAV are not eligible 
for the current iteration of hemophilia B gene therapy. In addition, recent advances in recombinant 
factor IX protein engineering have led some hemophilia treaters to reconsider the urgency of 
genetic cure. Current clinical and preclinical approaches to advancing AAV-based and alternative 
approaches to factor IX gene therapy are considered in the context of current demographics and 
treatment of the hemophilia B population.
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Factor IX gene therapy and the landscape of treatment for hemophilia B
Hemophilia B, resulting from deficient activity of clotting factor IX, accounts for 20% of 
hemophilia, while 80% of hemophilia results from deficient factor VIII activity (hemophilia 
A). Throughout most of the last half century, hemophilia B therapies have developed more 
slowly and often have been less available than treatments for hemophilia A. The description 
in 1964 of cryoprecipitate as a plasma preparation rich in factor VIII was a transformative 
moment in the care of hemophilia A, but large volume plasma infusion remained the only 
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source for replacement factor IX. Widespread availability of plasma-derived factor IX 
concentrates was delayed almost a decade after factor VIII concentrates became available in 
the 1970s. In response to the tragic contamination of plasma-derived factor concentrates 
with hepatitis and HIV, recombinant FVIII was generated and licensed by 1992; hemophilia 
B patients waited until 1997 in the U.S. (and much later in some countries) for the licensure 
of recombinant factor IX (rFIX), the last real innovation in hemophilia B care.
Then in a one month period between December, 2011–January, 2012, reports appeared that 
two goals had been achieved by new factor IX therapies: 1) the successful, persistent 
expression of factor IX by human gene therapy [1] and 2) the demonstration in a human 
clinical trial several-fold extension of factor IX circulating half-life via recombinant protein 
engineering [2]. Hemophilia A still awaits these successes. In the interim between January 
2012 and now, the licensure of a second recombinant factor IX (biosimilar rFIX concentrate 
having the wild type FIX molecular sequence and structure) expands product choice for 
conventional hemophilia B replacement therapy. During the same period three different 
approaches to modify the wild type factor IX protein have yielded comparable, >3-fold 
prolongations in the factor IX circulating half-life in human trials: the recombinant 
expression of factor IX monomer protein genetically fused to the constant region of 
immunoglobulin(rFIXFc); the recombinant expression of factor IX monomer protein 
genetically fused to albumin; and the modification of recombinant factor IX via the addition 
of a 40k polyethylene glycol moiety to the N-glycan acceptor sites at FIXAsn157 or 
FIXAsn167 (as reviewed by Kaufman and Powell) [3]. One rFIX fusion protein now is 
licensed (rFIXFc) and a U.S. Food and Drug Administration Biologic License Application 
has been submitted for the second (rIX-FP). This review limits its scope to considering how 
insights gained from three pioneering factor IX gene therapy trials have informed the 
objectives and design of several ongoing and planned trials of hemophilia B gene therapy. 
Hemophilia gene therapy’s first clinical success is reviewed in the context of an evolving era 
of choice for men with severe hemophilia B, while also considering the unique 
characteristics of this population (see Table 1) that currently limit the broad clinical 
translation of liver-directed adeno-associated virus (AAV) vector and other gene delivery 
approaches.
The first success: Adeno-associated virus vectors for the expression of 
factor IX
The first and only successful approach for human gene transfer of a coagulation factor used 
an adeno-associated virus (AAV) as the vector to deliver a human factor IX cDNA to the 
liver, the natural site of factor IX production [1] [4]. The wild type (wt) AAV is a small 
single-stranded DNA virus that is non-pathogenic and replication defective. Most 
individuals experience an asymptomatic exposure to wt AAV during childhood and mount a 
humoral immune response, which often results in persistent titers of anti-AAV antibodies 
sufficient to neutralize subsequent infection by wt AAV and by recombinant AAV vectors 
[5] [6] [7]. All coding sequences of the 4680 nt wt AAV genome are removed during the 
generation of AAV gene therapy vectors, adding further to their safety. Following 
transduction of the target cell, the recombinant AAV (rAAV) therapeutic gene sequences are 
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retained primarily as concatameric episomes and uncommonly integrate into the host 
genomic DNA.
Following the initial recognition that rAAV vectors transduce a variety of relatively end-
differentiated, non-dividing cells and tissues, the earliest attempts to correct hemophilia B 
targeted muscle expression. The capacity for intramuscular (I.M.) injection of AAV.FIX 
vectors to direct human factor IX expression and improve coagulation was demonstrated in 
mouse and dog models of hemophilia B [8] [9] [10] [11]. A Phase I clinical trial of 
AAV.FIX delivered to skeletal muscle commenced, sponsored by Avigen, Inc. Eight 
subjects were treated with a single strand rAAV serotype 2 vector following a single-dose, 
dose-escalation design via multiple direct I.M. injections. There were no safety concerns but 
also no sustained circulating factor IX activity was achieved [12]. Biopsy of injected skeletal 
muscle at 2–10 months after administration revealed persistence of the therapeutic transgene 
and factor IX protein not only intracellularly but also extensively bound to extracellular 
matrix collagen IV surrounding myocytes[13] [14]. Skeletal muscle from one subject 
examined at 10 years after AAV gene delivery demonstrated local persistence of vector-
derived FIX mRNA transcripts and FIX protein [15]. Recently, large animal studies have 
validated a strategy to achieve more efficient and uniform transduction of skeletal muscle by 
avoiding multiple local percutaneous I.M. injections and delivering rAAV.FIX to the entire 
vascular bed of limb muscles by using a peripheral transvenular approach [16].
AAV serotype 2 factor IX gene delivery to the natural site of factor IX expression in the 
liver was explored in mice and found to generate greater transgenic factor IX activity than 
equivalent vector doses delivered to the muscle; at least a part of the difference results from 
less efficient post-translational modification of factor IX in muscle when compared to the 
natural organ of synthesis of the protein. An unusual complication of severe hemophilia B, 
occurring in about 2–4% of patients treated with factor IX protein infusions, is the 
development of factor IX-specific IgG that neutralizes the procoagulant activity of factor IX 
(“factor IX inhibitors”). Not only is factor IX therapy rendered ineffective by this loss of 
“tolerance” of factor IX by the patient’s immune system (to which the factor IX appears to 
be a neoantigen) but potentially life-threatening anaphylactic reactions may be triggered by 
factor IX exposure. In the context of gene therapy, liver transduction in animals did not lead 
to loss of tolerance and factor IX inhibitor formation as readily as muscle gene delivery [10]. 
Multiple investigations have reproduced the observation that the tolerance of clotting factor 
following hepatic transduction by AAV does not result from anergy or immunologic 
ignorance of the potentially neoantigenic clotting factor, but results from the induction of 
tolerogenic regulatory T lymphocytes [11] [17] [18]. Convincing preclinical data for the 
liver-directed AAV approach was generated by showing that null mutation hemophilia B 
dogs having a high risk for factor IX inhibitor formation produced persistent circulating 
factor IX activity following hepatic delivery of AAV2.FIX, experienced decreased bleeding, 
and did not form factor IX inhibitors [12].
Avigen sponsored a human gene therapy trial delivering an AAV2.FIX construct with a liver 
specific promoter directly into the hepatic artery, reported by Manno [19]. At two lower 
doses no safety concerns or factor IX expression were observed, prompting escalation to the 
planned highest dose of 2 × 1012 Vector Genomes (VG)/kg. Circulating factor IX activity 
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peaked at 11.8% at 2 weeks after vector infusion, however factor IX then declined starting 
around 4 weeks after the AAV2 infusion, coincident with an ~ 10 times normal elevation of 
the liver transaminases ALT and AST. Peripheral blood T cells from a subsequent subject 
who received AAV2.FIX and experienced a less profound transaminitis suggested the most 
likely etiology was a cell-mediated adaptive immune response directed toward the liver[19] 
[20]. Following successful FIX gene delivery to hepatocytes, the capsid of the vector is 
degraded intracellularly and capsid-derived peptides are presented on the surface of the 
transduced hepatocyte in the context of MHC class I molecules. At relatively higher 
exposures of AAV capsid, memory T cell recognition of AAV capsid peptides then may 
trigger a cytotoxic lymphocyte (CTL)-mediated elimination of AAV-transduced 
hepatocytes.
Several strategies were subsequently incorporated into AAV.FIX vectors to increase the 
efficiency of liver transduction, so that the vector particle dose and potential immune 
recognition of AAV could be minimized. The rhesus macaque is the natural host for AAV8 
and the seroprevalence of AAV8-neutralizing antibodies (NAb) in humans is lower than 
AAV2 NAb [6] [7] [5]. AAV8 transduces liver more efficiently than AAV2 and with less 
off-target distribution in organs outside the liver, allowing infusion by peripheral vein rather 
than the invasive hepatic artery route [21]. A rate-limiting step in AAV transduction, which 
is the need to convert single strand AAV into a double-stranded configuration to serve as a 
template for transcription, was overcome by using self-complementary (sc) AAV vectors, 
increasing transduction efficiency [22] [23] [24]. Conservative nucleotide changes leading to 
codon optimization also yielded robust increases in factor IX expression [17] [24].
In 2011 St Jude Children’s Research Hospital and the University College London (UCL/
SJCRH) investigators reported the first hemophilia trial to achieve persistent clotting factor 
expression [1] [4]. Following the single scAAV8.FIX codon-optimized vector 
administration all ten subjects in the trial decreased markedly their use of exogenous factor 
IX protein infusions. Steady state expression of factor IX activity for the six subjects treated 
at the highest dose (2 × 1012 VG/kg) maintained a mean of 5.1 ±1.7%, measured at least a 
year after vector administration. At this high dose, however, 4 of 6 subjects developed AAV 
capsid-specific T lymphocyte responses at 7 to 10 weeks after vector administration. The 
pro-inflammatory T effector cell responses were temporally associated with transient alanine 
aminotransferase (ALT) increases to 1.5–4 times the upper limit of normal in two subjects; 
two additional subjects demonstrated an increase above their individual baseline, although 
the ALT remained in the normal range. Corticosteroid therapy was initiated promptly in 
response to the transaminase changes and continued for 8–12 weeks. Despite a decline in 
factor IX expression in these four subjects some factor IX expression has been maintained in 
all subjects, which is an encouraging improvement over the outcomes in the ssAAV2 liver 
trial. The first subject treated has expressed 2% factor IX steadily for more than 4 years of 
follow up.
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Ongoing and planned hemophilia B clinical trials using the adeno-
associated virus vector
The UCL/SJCRH study investigators describe the hepatic inflammation seen in their high 
dose study subjects as a manageable toxicity. Nevertheless, the complication limits the 
ability to offer the therapy to adults with hemophilia who are active carriers of hepatitis or to 
increase the vector dose to achieve truly normal hemostasis (e.g. to achieve baseline factor 
activity of ≥15% that is expected to prevent all joint bleeding) [25]. Subsequent to the 2011 
report, three AAV8.FIX trials have commenced with the goal of achieving greater factor IX 
expression without toxicity. The UCL/SJCRH clinical vector contained, in addition to the 
therapeutic scAAV8.FIXco, empty AAV8 capsids carrying no FIX gene [26]. These 
contaminating empty AAV capsids comprised 80% of the vector preparation and were a 
potential trigger for the dose-dependent CTL response directed against AAV. The AAV 
vector manufacturing process at the University of North Carolina at Chapel Hill Vector Core 
Facility incorporates empty capsid removal steps. Vector made at this facility containing less 
than 10% empty capsids is being used in a trial sponsored by Baxter Healthcare, testing a 
scAAV8.FIX vector designated BAX335 [27, 28]. Purification steps that remove empty 
capsids are now employed by the UCL/SJCRH group, resulting in a 90% “full” capsid 
vector stock [29]. Each of these two groups is currently enrolling subjects to test whether 
scAAV8 vector having minimal empty capsid contamination will permit dose escalation 
without stimulating cell-mediated immunity.
Investigators at the Children’s Hospital of Philadelphia (CHOP) proposed an alternative 
approach to the empty capsids, theorizing that the defective particles may have aided AAV 
transduction in the UCL/SJCRH trial. Mingozzi and colleagues suggested that empty 
capsids titrated into therapeutic AAV vector preparations could act as “decoys” in the 
eventuality that circulating AAV NAb were present, thereby allowing therapeutic virus to 
evade neutralization and transduce liver more efficiently. This strategy was to be 
incorporated into a single-stranded AAV8.FIX trial [30]. A clinical trial initiated by these 
investigators (sponsored by Spark Therapeutics) has yet to be reported [31].
Given that a vector dose-dependent immune response is the only toxicity of AAV.FIX 
observed to date in humans, and the fact that capsid epitopes from empty capsids that enter 
cells may contribute to the CTL response, the CHOP investigators next introduced further 
mutations at amino acids 585/588 of their decoy capsids to disrupt the AAV2 binding for 
heparin sulfate (HS), the receptor for AAV on hepatocytes [30]. The investigators showed in 
mice that these mutations prevented receptor-mediated hepatocyte entry by the decoy empty 
capsids, presumably eliminating the ability of the hepatocyte to present capsid-derived 
peptides and trigger a hepatocyte-targeted CTL response. The use of excess HS-non-binding 
(585/588 mut) decoy capsids has not been tested in human application. One concern is that 
Kern and colleagues have previously shown that, although hepatocyte entry is lost in mutant 
rAAV585 capsids, entry into cardiac muscle is maintained or increased, and so the potential 
exists that the CTL could be redirected from liver to myocardium [32].
An alternative approach to achieve higher factor IX activity without increasing vector 
exposure, now validated in preclinical work, is to employ a gain-of-function variant of factor 
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IX. Structure-function studies of the catalytic domain of factor IX in the Stafford laboratory 
revealed that substitution of alanine for arginine at amino acid 338 in the catalytic domain 
increased the specific activity of factor IX [33], and Simioni and colleagues subsequently 
characterized a family that expressed a hyperactive factor IX as a result of a leucine 
substitution at this same amino acid (FIXR338L) [34]. Multiple groups have now 
demonstrated in hemophilia B animal models that the incorporation of FIXR338L (Factor 
IX Padua) into AAV vectors for transduction of liver [35] or muscle [16], or into lentiviral 
vectors for transduction of liver [36] [37] leads to the expression of factor IX protein having 
at least 6–8 times normal specific activity without an increased incidence of thrombosis. 
Crudele and colleagues recently reported that AAV8-mediated hepatic expression of 
FIXR338L was associated with the development of factor IX tolerance in FIX inhibitor-
prone hemophilia B dogs, as well as eradication of the pre-existing factor IX inhibitor in one 
dog [17]. Preclinical data has been reported recently that supported the initiation in 2013 of 
a human trial of the scAAV8FIXR338L codon-optimized BAX335 vector (the vector 
introduced above), with trial results pending [35].
Spark Therapeutics and Dimension Therapeutics each have promised Phase 1 trials for 
hemophilia B using proprietary AAV capsids; additional details are not publicly available. 
Uniqure has initiated a European Phase 1/2 trial using the identical factor IX expression 
cassette (LP1-hFIXco) used in the UCL/SJCRH trial, packaged within an AAV serotype 5 
capsid instead of AAV serotype 8 and delivered via peripheral vein. Interestingly, the LP1-
hFIXco expression construct pseudotyped with AAV5 and with AAV8 has previously been 
compared in non-human primates by Nathwani and colleagues [21]. Although the studies 
demonstrated comparable liver transduction and factor IX expression using AAV5- or 
AAV8-pseudotyped vectors, the two serotypes were not interchangeable. Following 
peripheral vein administration, when compared to scAAV8-LP1-hFIXco, the expression was 
slower from AAV5-pseudotyped sc-LP1-hFIXco, the clearance of vector genomes from 
plasma more delayed, and the off-target transduction of spleen, kidney and testis were 
greater for the serotype 5-pseudotyped vector. The investigators’ conclusion was that 
scAAV8 capsid proteins are preferable for liver transduction via peripheral vein but that 
scAAV5-pseudotyped vectors should be effective for treating individuals with pre-existing 
immunity to AAV8 or AAV2 [21]. Should pre-existing AAV8 NAbs limit enrollment in 
clinical trials, the Uniqure AAV5-pseudotyped vector might prove advantageous. A recent 
study of prevalence of naturally-occurring antibodies against AAV serotypes conducted in a 
healthy European population documented neutralizing antibody seroprevalence of 59% for 
AAV2, 19% for AAV8 and 3% for AAV5 [7]. Higher seroprevalence of AAV5 NAbs has 
been reported in other populations [38] [39], and the lack of concensus regarding a 
standardized methodology for NAb measurement complicates comparison between studies. 
The only AAV NAb study of a similar size evaluated in a hemophilia population is a 
pediatric study showing that by age 5–6 years boys with hemophilia had NAb 
seroprevalence of 27% for AAV2, 13% for AAV8 and 15% for AAV5 [6]. Uniqure has 
presented in abstract form a safety and dose-finding study in non-human primates to justify 
the trial design [40]. Five subjects will be treated with AAV5-hFIX 5.0 × 1012 VG/kg, 
followed by an escalation to 2.0 × 1013 VG/kg to treat the final five subjects.
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Sangamo BioSciences in collaboration with Shire AG has announced plans for a human trial 
of factor IX gene editing using AAV to deliver zinc finger nuclease (ZFN) technology. The 
planned trial is based on work from the research group of High, in collaboration with 
Sangamo, who used a hemophilia B mouse model, engineered to carry a human nonsense 
mutant Y155stop F9 minigene inserted in the ROSA26 locus (hF9mut mice), to examine 
ZFN gene correction in vivo. The delivery of AAV8 ZFN to target intron 1 of the F9 gene 
along with a second AAV8 donor template vector with arms of homology flanking F9 exons 
2–8 to neonatal mice (i.e. mice undergoing rapid growth of the liver) as well as adult mice 
resulted in apparent ZFN-induced double strand breaks in host DNA and homology-directed 
repair of the F9 gene [41]. Co-delivery of AAV8 expressing the hF9-specific ZFN and 
AAV8 expressing the corrective partial F9 cDNA was able to direct sustained expression 
averaging 23% of normal human factor IX in the adult hF9mut mouse model.
Although gene editing is an exciting direction for the field, several caveats exist with the 
work described to date. Off-target cleavage by the ZFN vector remains a concern (for 
example, treatment of WT littermates lacking the ZFN target site nevertheless led to 
expression of 1% normal human factor IX) [42]. Rates of off-target cleavage differ between 
ZFN and more recently developed nuclease systems that systems that are finding application 
in hemophilia gene and cell therapy [43], such as transcriptional activator-like effector 
nucleases (TALENS) and the two-component CRISPR (clustered regularly interspaced short 
palindromic repeat)– Cas9 (CRISPR-associated nuclease 9). Off-target rates depend not only 
on the nuclease reagent but also how long and at what level the nuclease is expressed and 
how many likely off-target sites exist in the genome from the outset. The AAV8.ZFN F9-
targeting dual vector strategy described above provided for constitutive, rather than 
transient, expression of the ZFN by AAV vector transduced cells. This creates the potential 
for generation of an immune response against the ZFN (as a foreign protein), as well as the 
possibility for lasting genomic instability due to long-term low-level ZFN-mediated 
genomic damage. Furthermore, although ZFN-mediated gene editing is expected to 
introduce permanent gene correction (when compared to an episomally located AAV-
delivered factor IX transgene), the proposed approach did not circumvent the need for doses 
of AAV vector that have been immunogenic in the previous hemophilia trials; the equivalent 
of 2.4 × 1013 VG/kg of the combined AAV vectors was used to promote gene correction in 
the murine model (i.e. ten times greater vg/kg dose than the dose associated with 
transaminitis in the Avigen and UCL/SJCRH trials). For human clinical application, 
Sangamo has developed an alternative approach in which F9 gene insertion is targeted 
downstream of the highly active albumin promoter, potentially driving robust factor IX 
production while requiring fewer vector particles/integration events than were required in 
the mouse studies. Such an approach may not require a nuclease to promote site-specific 
recombination [44].
An unknown regarding the ultimate potential for AAV gene therapy to provide a cure for 
hemophilia B is how long transgene expression from this non-integrating vector will persist, 
particularly in tissues like the liver that are felt to undergo some degree of turnover (albeit at 
a slow rate). The F9 transgene integration status and the persistent, stable expression of 
AAV-delivered factor IX from the livers of the null-mutation dogs has been extensively 
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characterized at 8 years of follow up and subsequent reports confirm phenotypic correction 
for >10 years [45] [11]. Likewise, ongoing hepatic factor IX expression for greater than 8 
years continues to be followed in non-human primates [4]. Consistent with the large animal 
experience, the first subjects treated on the UCL/SJCRH trial continue to demonstrate stable 
factor IX expression for greater than four years and counting.
Preclinical Development: Lentivirus vectors for liver gene therapy
Lentiviruses (LVs) efficiently transduce the relatively quiescent hepatocytes along with 
multiple cells of the liver. These include antigen-presenting cells, and a major task for 
adapting lentiviruses for hemophilia gene therapy has been to avoid immune responses to 
the potentially neoantigenic factor IX and factor VIII. In regard to factor IX, restricting gene 
expression to the liver with the use of liver-specific promoters and opposing gene expression 
in APCs via the incorporation of hematopoietic-specific microRNA target sequence 
(miR142-3p) achieved factor IX expression in and secretion from the liver in both mouse 
and dog models of hemophilia B [46] [47]. Moreover, lentivirus-directed liver-restricted 
factor IX expression appears to actively promote tolerance induction via the induction of 
CD4+ CD25+ Foxp3+regulatory T cells (Tregs) [47]. Tolerance induction and eradication of 
pre-existing factor IX inhibitors has recently been demonstrated following liver-restricted 
LV.FIX transduction [18].
Given somewhat less robust factor IX expression from LV (when compared to several 
serotypes of AAV) much recent emphasis has been on LV development for the task of 
delivering the large F8 gene, which is very difficult to accommodate in tiny AAV vectors 
[47] [48]. Investigation of the concern that LV genomic integration could cause genotoxicity 
is the subject of active investigation, and appears to be considerably lower risk than has been 
observed with the use of gamma retroviral vectors [46]. Nevertheless, several groups have 
addressed the concern of potential genotoxic risk by engineering lentiviral vectors with 
inactivating mutations in the integrase to create integration-defective lentiviral vectors. 
Although the transgene expression is reduced by loss of integration, optimization of the 
vectors and incorporation of gain-of-function FIXR338L transgene has achieved disease 
correction in hemophilic mice, while maintaining the potential for factor IX tolerance 
induction by hepatic expression [46] [36] [37] [47].
Preclinical Development: Cell-based approaches
Lentivirus-mediated delivery of the F9 gene has also been employed in a cell-based 
approach that results in circulating platelet delivery of factor IX to maintain hemostasis [49]. 
Adapting an approach that has demonstrated phenotypic correction in large animal models 
of hemophilia A and Glanzmann Thrombasthenia [50], a LV construct expressing human 
factor IX under the control of the platelet-specific glycoprotein IIb gene (αIIb) promoter was 
used to transduce FIX−/− mouse hematopoietic stem cells (HSC) ex vivo. Recipient FIX−/− 
mice were conditioned for HSC transfer with either a myeloablative (1100 cGy) or a 
nonmyeloablative (660 cGy) dose of total body irradiation 24 hours prior to infusion of the 
LV-transduced HSCs. Although negligible factor IX activity was measurable in plasma, 
human factor IX expression was present in cells of megakaryocyte lineage, co-localized with 
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Von Willebrand Factor, provided partial hemostatic protection during a bleeding challenge, 
induced tolerance to human factor IX in FIX−/− mice, and could be transferred via bone 
marrow transplant to secondary recipient FIX−/− mice. Moreover, the nonmyeloablative 
conditioning was adequate to achieve all of these outcomes. Interestingly, an LV strategy 
employing a platelet-specific factor VIII expression cassette has recently been demonstrated 
to transduce hematopoietic stem cells and lead to correction of the hemophilia A bleeding 
phenotype in mice following direct intraosseous LV delivery with no requirement for a bone 
marrow conditioning regimen [48]. The latter approach has not been explored for the 
correction of hemophilia B.
Severe hemophilia B: Goals and Options
It has been stated many times that hemophilia B is an ideal disease model for the 
investigation of gene therapy approaches [47] [1]. It is worthwhile to examine the target 
patient population of adult men with severe factor IX deficiency and consider whether gene 
delivery in its current application is the ideal therapeutic approach and what patient-related 
factors may determine whether and how gene therapy translates from a primarily academic 
effort into wider clinical application.
An unprecedented time of new treatment options for men with severe hemophilia B 
approaches. An examination of the self-reported outcomes of men with severe factor IX 
deficiency captured by the U.S. surveillance instrument (Table 1) reveals that a third of men 
report potentially damaging high rates of joint bleeding (adjusted joint bleeding rate ≥10/yr), 
while the adoption of regular factor IX prophylaxis is low. (Table 1) Adherence to 
prophylactic infusions is an unrelenting demand whether the goal is to reduce bleeding or 
prevent it altogether. Hemophilia patients and physicians have recently been presented with 
three studies taking different approaches to maintaining joint health. One study compared 
on-demand therapy with unmodified recombinant factor IX (rFIX, Benefix®, Pfizer) using 
either a conventional approach to factor IX prophylaxis (50 IU/kg) twice weekly or a higher 
dose once-weekly (100 IU/kg) regimen. There were no treatment-related safety concerns. 
The mean annualized bleeding rates (ABR) were 35.1, 2.6, and 4.6 bleeding events/year for 
the on-demand, the twice-weekly therapy and the once-weekly therapy. The rationale for 
conventional twice weekly therapy is to maintain measurable (>1% activity) trough factor 
IX concentrations throughout a week; the higher once-weekly dose would be expected to 
result in some portion of the week with unmeasurable circulating factor IX, Nevertheless, 
there was no statistical difference between the ABR for the two prophylaxis approaches 
(P=0.22) [51]. These study results and others justify investigation of the possibility that 
factor IX bound in extracirculatory sites may contribute to hemostasis [52] [53]. 
Understanding the amount and the physiologic relevance, if any, of the factor IX distributed 
in extracirculatory sites could be relevant for understanding the total endogenous factor IX 
expression required from gene therapy.
A separate study compared recombinant factor IX Fc fusion protein (rFIXFc, Alprolix®, 
Biogen Idec), a newly licensed extended circulating half-life factor IX, infused on demand 
for bleeding events, compared to either 1) rFIXFc prophylaxis infused weekly and starting at 
a dose of 50 IU/kg or 2) prophylaxis infused at a dose of 100 IU/kg every ten days. Trough 
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factor IX activity levels were obtained regularly and the dose of the lower prophylaxis dose 
was adjusted during the trial to maintain trough plasma factor IX activity 1–3%; the interval 
of the higher prophylaxis dose was adjusted to target the same trough levels. The median 
annualized bleeding rates were 17.7, 3.0, and 1.4 bleeding events/year for the on-demand, 
the lower dose, weekly therapy and the higher dose, less frequent therapy, with no statistical 
difference between the two prophylaxis approaches (P=0.22) [51]. There were no treatment-
related safety concerns. The third recent study to consider alongside the rFIX and the 
rFIXFc studies is the UCL/SJCRH gene therapy trial, in which six subjects received the 
highest dose of 2 × 1012 VG/kg of scAAV2/8-LP1-hFIXco vector. This dose resulted in 
mean steady state plasma factor IX activity of 2.9–7.2% for the six subjects, a median 
annual bleeding rate of 1.0 episodes, and a relative 94% reduction of bleeding compared to 
before gene therapy [4]. Laboratory monitoring was intensive for the first four months of the 
trial and then tapered. Four of six participants received 8 to 12 weeks of corticosteroids to 
treat vector-associated hepatic inflammation. These examples of choices and outcomes are 
offered as a reminder that progress in gene therapy occurs in the context of constant shifts in 
hemophilia care standards and community outlook.
To illustrate an example of a developed world country, Table 1 compiles available data for 
the population of men with severe hemophilia B in the United States (keeping in mind that 
80% of men with hemophilia B live in developing countries and have no access to factor IX 
therapy). While there are approximately 1000 men in the U.S. who could be eligible for 
gene therapy trials based on factor IX activity ≤2 % of normal (≤2 U/dl), the relative and the 
absolute exclusionary criteria that apply to liver-directed AAV.FIX trials (ongoing or 
planned) considerably narrow the eligible population.
The hepatocyte-directed immune response that has been elicited by AAV capsid epitopes at 
the most therapeutic vector doses drastically limits the eligibility of men over the age of ~ 
30 years due to the high hepatitis B virus (HBV) and hepatitis C virus (HCV) carrier 
prevalence in this population. Almost 80% of the adult severe hemophilia B population in 
the United States, for instance, is seropositive following exposure to HCV. Rates of active 
carrier state (HCV PCR +) are not available for the hemophilia population. Although it is 
likely that spontaneous clearance of HCV may occur in as many as 20% of HCV exposures, 
at the start of the current decade most HCV Ab+ hemophilic men in the U.S. had never 
received therapy to attempt to eliminate the HCV carrier state. The last two years have 
witnessed the advent of new and well tolerated antiviral agents that are effective against 
even the most historically resistant strains of HCV. It can be hoped that eliminating active 
HCV will be a major accomplishment in hemophilia care in the next decade. Men who have 
a sustained HCV clearance response following therapy and no evidence of liver failure are 
eligible for AAV.FIX therapy and one consequence of eliminating the HCV carrier state 
would be to broaden the eligible population for systemic gene delivery. Alternatively, 
continued development of gene therapy targeting non-hepatic tissues (e.g. targeting muscles, 
joints, hematopoietic stem cells including platelets) may present the safest approaches in this 
large subset of individuals with hepatitis. [16] [53] [48] [49].
Although it is uncommon for inhibitors to complicate hemophilia B, the history of a factor 
IX inhibitor antibody is exclusionary for all current gene therapy trials [54]. As discussed 
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above, multiple small and large animal studies have demonstrated that steady state 
endogenous factor IX expression via gene therapy may promote tolerance via the induction 
of factor-specific regulatory T cells (e.g. platelet-targeted gene expression) or even eradicate 
pre-existing factor IX inhibitors (as has been demonstrated via hepatic expression following 
AAV or lentivirus factor IX gene delivery) [55] [56] [18] [49]. Clinically, factor IX 
inhibitors are often associated with hypersensitivity reactions, and there are no reliable 
predictors of the risk or timing of the reactions. A deliberate attempt to reverse a factor IX 
inhibitor by constitutively expressing factor IX using an expression cassette that cannot be 
silenced involves some risk of triggering hypersensitivity that cannot be controlled. It is 
intriguing to consider combining formal factor IX desensitization or anti-IgE monoclonal 
antibody therapy with liver-directed gene therapy as a potential therapy for the very difficult 
clinical complication of allergy-associated factor IX inhibitors.
An additional immunologic consideration already mentioned is the growing understanding 
that pre-existing NAbs against AAV may cross-neutralize multiple serotypes of AAV and 
abrogate vector transduction at very low titers (e.g. neutralizing titers of 1:5 to 1:10) [57]. 
Older prevalence studies of AAV NAbs often defined as a lower limit of detection titers of 
1:20 or higher, and methods of detecting neutralizing antibodies are not uniform between 
laboratories, so that the scope of AAV NAb interference remains unclear. Standardization of 
methods will be critical as the nascent field of hemophilia gene therapy grows beyond 
isolated, primarily academic trials and into multiple concurrent industry-supported trials. 
Implementation of a recently reported reference standard for the titering of AAV serotype 8 
viral vectors is an important first step in being able to rationally compare dose-response and 
dose-toxicity results between clinical trials [58]. Currently children are excluded from gene 
therapy trials for diseases that do not cause death or great morbidity in childhood. It has 
been shown that once infants lose maternally transferred AAV NAb, there is a window 
around one year of life when essentially 0% of infants have AAV NAb [5]. Should liver-
directed AAV gene therapy prove to be safe, to support factor IX tolerance and concerns 
about NAbs (and perhaps by extension also memory lymphocyte-driven CTL response)in 
infants are minimal, then broadening the application of gene therapy to children could be 
advantageous.
Following decades of limited choices regarding hemophilia B therapy, patients and their 
doctors now may consider variety of protein and (in the context of clinical trials) gene 
therapies. While gene therapy involves the most uncertain risks, extended therapeutic benefit 
has now been demonstrated in a human clinical trial. With multiple additional trials ongoing 
or commencing, one can expect that additional knowledge and experience will facilitate the 
discussion between patients, families and their doctors about how gene therapy may fit into 
the therapeutic options for hemophilia B.
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Characteristics of adult severe hemophilia B population in the United States
Proportion of adult male hemophilia B population (%)
Severe Hemophilia B (FIX:C <1%) 1 35.7%
Factor IX Inhibitor (+) 2 2%
Factor IX Inhibitor (−) 2 98%
Proportion of Severe Hemophilia B Population (%)
Adult men (Total) Adult men <30 years old
Factor IX infused on regular prophylactic schedule? 3 24.7% 37.0%
Annualized Joint Hemorrhage Rate ≥ 10 38% 30%
Hepatitis B seropositive 51.2% 5.7%
Hepatitis C seropositive 4 77% 41.4%
Chronically elevated liver transaminases? 18.5% 4.8%
If Hepatitis C antibody (+):Ever received anti-viral therapy for hepatitis C?
 No 76% 74%
 Yes 24% 26%
If yes, Sustained viral response to therapy? 54% 61%
HIV/HCV co-infection 20% 1.3%
N/A = Not available.
Sources used to compile the table include national data collected and verified through 2011 [54] [59] [60] [61]. Shaded characteristics are 
exclusionary criteria for all current Hemophilia B gene therapy clinical trials.
1
Current gene therapy trials for hemophilia B typically include individuals with ≤ 2% factor IX and clinical history of frequent hemorrhage. In 
addition to the 791 adult men with <1% activity in the U.S., an additional 165 men potentially meet inclusion criteria based on baseline factor IX 
activity 1–2%.
2
The U.S. Centers for Disease Control and Prevention Universal Data Collection captures current and new incident inhibitors but does not capture 
individuals with a history of inhibitor who have no current inhibitor titer. History of factor IX inhibitor is exclusionary for current gene therapy 
trials.
3
Categorized as prophylaxis if, during the year preceding the visit, factor infusions were used on a regular schedule to prevent any and all bleeding 
and this therapy was expected to continue indefinitely.
4
Data are not available on the proportion of HCV-exposed (seropositive) individuals who have active disease as demonstrated by PCR of HCV 
RNA; in addition to individuals having a sustained viral response to HCV therapy, at least 20% of HCV-infected individuals may spontaneously 
clear HCV.
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